sr 2555 has been researched along with EHS Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, DM; Brown, JM; Lee, WW; Yu, NY | 1 |
| Siemann, DW | 1 |
2 other study(ies) available for sr 2555 and EHS Tumor
| Article | Year |
|---|---|
SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.
Topics: Animals; Carcinoma; Cell Line; Central Nervous System; Cricetinae; Dogs; Etanidazole; Female; In Vitro Techniques; Lipid Metabolism; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; X-Rays | 1981 |
Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
Topics: Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etanidazole; Female; Leukocyte Count; Lomustine; Metronidazole; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Nitrosourea Compounds; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1982 |